Welcome to the BCMA Targeted Therapies Summit| Workshops are Now Live

BCMA Home Banner

Welcome to the BCMA Targeted Therapies Summit

Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK’s ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.

With such a well validated target, rapid advances and growing excitement in the field, the inaugural BCMA Targeted Therapies Summit is industry’s first dedicated discussion and networking forum focused on bringing together the thought-leaders within the BCMA field to share the latest scientific progress and address the current challenges drug developers are facing.

Developed with experts from Amgen, Kite Pharma and Legend Bio and other leading organizations, join 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions. Hear from over 20 experts sharing preclinical data for next generation BCMA targeted therapies, bringing in the patient perspective and exploring efficacy of patient response from the clinic.

You will leave this in-depth online learning experience with a deeper understanding of the discovery, preclinical and clinical landscape of BCMA Targeted Therapies.

Among Your World Class Speaker Faculty

Dexiu Bu

Senior Principal Scientist

Novartis

Matthias Friedrich

Scientific Director

Amgen

Raluca Verona

Senior Director, Head of Immune Oncology & Translational Research

JnJ

Regina Lin

Principle Scientist

Allogene

Timothy Campbell

Senior Medical Director in Translational Medicine

BMS